ANEB Anebulo Pharmaceuticals, Inc.Stock Price & Overview
$2.36-0.01 (-0.42%)3:32 PM 12/04/23
NASDAQ | $USD | Post-Market: $2.43 +0.07 (+2.97%) 4:09 PM
People Also Follow
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company’s lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.